|10/9/12||(CPHD) Cepheid’s Preliminary 3Q Disappoints (Stock Blog Hub)|
After reporting a disappointing second quarter 2012, Cepheid’s (CPHD) preliminary results for the third quarter of 2012 were also below the consensus estimate. The company is likely to report revenues in the range of $79?$81 million, while the current Zacks Consensus Estimate stands at $84 million for the third quarter. As per the Zacks Consensus [...]
|10/5/11||CPHD (Samurai Trader)|
One of the great things about the price relative line is it gives you an instant picture of the relative strength of the stock. One of the weaknesses is that it has no idea why the stock is strong. I have no idea why CPHD has so far refused to sell odd with the rest of the market, and today's failed breakout suggests it might not be as strong as it looks, but when a stock is hanging in there like this one, it does grab your attention.
|10/5/11||CPHD, MG, QCOR, TSPT Among Charts to Watch (Wall Street Sector Selector)|
It was turn-around Tuesday, indeed, especially the last 45 minutes with a monster rally. The Dow ran 400 points in 40 minutes, the S&P 500 about 50, and the Nasdaq 100 about 98. A lot of stocks rebounded, but most importantly are the stronge...
|6/28/11||(CPHD) Cepheid Targets Infectious Diseases (Stock Blog Hub)|
Cepheid (CPHD) announced the appointment of Robert Kwiatkowski as the Vice President of Infectious Disease Research and Development. He would be reporting to David Persing, the company’s Chief Medical and Technology Officer. Dr. Kwiatkowski walks into Cepheid with extensive experience in nucleic acid infectious disease test development and management, including tests for HPV, HIV and HCV. [...]
|10/7/10||Cepheid Collaborates With Novartis on Chronic Myelogenous Leukemia (Benzinga)|
Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management. The collaboration reflects the commitment shared by Novartis and Cepheid to deliver the...
|1/6/10||(CPHD) Cepheid’s H1N1 Test Earns Emergency Use Authorization (Stock Blog Hub)|
Recently, Cepheid (CPHD) received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Xpert Flu A Panel test, which is for identifying the H1N1 influenza virus in less than one hour. Given the swine flu scare, we expect Cepheid to benefit significantly from the introduction of this test. The FDA [...]
|11/29/09||(CPHD) Cepheid Narrows Loss (Stock Blog Hub)|
Cepheid’s (CPHD) third quarter net loss per share of 6 cents was much better than the Zacks Consensus Estimate of 12 cents as well as a loss of 12 cents reported in the third quarter of 2008. Although revenues for the quarter came down by 7% to $41.6 million, the company managed to reduce its [...]